Elan bids not expected until after results

First round takeover bids for Irish bio-tech firm Elan are not likely to be formally tabled until after the company publishes its half-year results later this month.

It was reported at the end of last week that Elan would be formally seeking initial bids this week.

However, sources close to the company have since claimed that suggestions of such a timeframe are “inaccurate”.

The Dublin-based company effectively put itself on the market last month, by opening a formal sale process.

That move coincided with shareholders narrowly rejecting a hostile takeover approach from US intellectual property firm, Royalty Pharma.

While a number of US firms have been mentioned as potential suitors, recent commentary has suggested that Royalty could still benefit, mainly through buying Elan’s Tysabri royalties from the company’s new owner.

Most recent reports have linked the likes of US pharmas Forest Laboratories and Botox-maker Allergan — both of which have a manufacturing presence in Ireland — with a move for Elan.

A spokesperson for Elan declined to comment yesterday.

Elan is set to publish its second-quarter/first-half financial results next Wednesday.

Elan’s Dublin share price was up by just under 1% yesterday, closing at €10.69.


Lifestyle

The world is in chaos and fascism is on the march. But enough about 2020 – what about America in 1940?The Plot Against America: Sky Atlantic series shows a parallel history that has echoes of today's world

Ubisoft has given us a look of some of their upcoming releasesGame Tech: A glimpse of Far Cry 6 and Assassin’s Creed Valhalla

Exfoliating cleansers are the first step in upgrading your skincare routine.The Skin Nerd: How to get active when it comes to cleansing

The arrival of the new baby has led to a tricky family dynamic in the Cork-set show, writes Georgia HumphreysBaby's arrival leads to more adventures as the Young Offenders return

More From The Irish Examiner